Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
RNA therapeutics have emerged as a promising class of medications for treating a range of diseases, including cancer, genetic disorders, and infectious diseases. Among them, synthetic messenger RNA (mRNA) has drawn much attention due to its versatile use in exogenous protein expression. Originally, mRNA is an endogenous single-stranded RNA molecule that transfers genetic information from DNA to proteins. This intermediary molecule is essential for gene expression and allows the production of target proteins in the cytoplasm through a single translation step. After the development of in vitro transcription systems in the 1990s, synthetic mRNA has emerged as an alternative tool for expressing target proteins in cells. Compared to other gene expression systems such as plasmid DNA (pDNA) and viral vectors, synthetic mRNA has several advantages such as simple intracellular processing, rapid and robust gene expression, and convenient manufacturing. However, the delivery of synthetic mRNA molecules to target cells and tissues remains a major challenge due to their fragile nature and susceptibility to degradation.
To overcome these limitations, lipid nanoparticles (LNPs) have received much attention as a versatile and efficient delivery system for mRNA therapeutics. Lipid nanoparticles play a crucial role in the development of mRNA therapeutics by enabling the efficient delivery of RNA molecules into target cells and tissues.
Optimizing RNA delivery systems is critical for the development of effective RNA therapeutics. Messenger RNA is a relatively large molecule (10-10 Da), which largely prevents its diffusion into cells, and its negative charge makes its transport through the anionic cell membrane challenging. In addition, mRNA is unstable and susceptible to degradation by several enzymes, including 5' or 3' exonucleases and endonucleases. LNPs have been shown to effectively encapsulate RNA molecules and protect them from degradation, enabling them to enter cells and perform their therapeutic functions. Moreover, LNPs can overcome several biological barriers by allowing endosomal escape, cellular uptake, and drug release, enhancing the therapeutic efficacy of synthetic mRNA. As a result, LNPs have become a widely used platform for the development of mRNA therapeutics, particularly in the context of vaccines and gene therapies.
We offer ready-to-use LNP encapsulated mRNA & circular RNA with high quality and in vitro & in vivo activity. These products can be used as the control of your RNA experiment for both in vitro & in vivo applications, or to assess the efficiency of LNP-based RNA delivery systems.
| Cat.No. | Product Name | Price |
| PMCRL-0001 | EGFP circRNA-LNP | Inquiry |
| PMCRL-0002 | Firefly Luciferase circRNA-LNP | Inquiry |
| PMCRL-0003 | Gaussia Luciferase circRNA-LNP | Inquiry |
| PMCRL-0004 | Renilla Luciferase circRNA-LNP | Inquiry |
| PMCRL-0005 | mCherry circRNA-LNP | Inquiry |
| PMCRL-0006 | OVA circRNA-LNP | Inquiry |
| PMCRL-0007 | EPO circRNA-LNP | Inquiry |
| PMCRL-0008 | CD19 CAR circRNA-LNP | Inquiry |
| PMCRL-0009 | Spike SARS COV-2 circRNA-LNP | Inquiry |
| PMCRL-0010 | HER2 circRNA-LNP | Inquiry |
| PMCRL-0011 | p53 circRNA-LNP | Inquiry |
| PMCRL-0012 | PD1 circRNA-LNP | Inquiry |
| PMCRL-0013 | IL2 circRNA-LNP | Inquiry |
| PMCRL-0014 | Luciferase P2A GFP circRNA-LNP | Inquiry |
| PMCRL-0015 | Cas9 circRNA-LNP | Inquiry |
| PMCRL-0016 | Sox2 circRNA-LNP | Inquiry |
| PMCRL-0017 | Oct4 circRNA-LNP | Inquiry |
| PMCRL-0018 | Klf circRNA-LNP | Inquiry |
| PMCRL-0019 | c-Myc circRNA-LNP | Inquiry |
| PMCRL-0020 | Lin28 circRNA-LNP | Inquiry |
View more of our premade RNA-LNP products
LNPs have demonstrated enormous potential as in vivo delivery platforms for RNA therapeutics, such as small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and mRNAs. There are several FDA-approved RNA therapies for gene therapy, including three LNP formulations of RNA therapies. However, with the exception of mRNA vaccines for COVID-19 that have been authorized for emergency use, the majority of mRNA therapeutics for protein replacement therapies and gene editing are still in the stage of preclinical development. Although LNPs hold great promise as a delivery system for RNA therapeutics, several challenges remain and must be addressed before expanding the applications of RNA/LNPs to treat various diseases. One of the primary challenges is achieving extrahepatic delivery of RNA to specific organs or cells.
While LNP is a promising drug delivery system, major accumulation of LNP in the liver by ApoE-LDL interaction has hindered the successful development of mRNA/LNPs to treat extra-hepatic diseases. To expand the use of LNPs to target extra-hepatic organs, it is necessary to develop strategies to effectively target specific organs and tissues in the body. Therefore, new approaches have been investigated to deliver therapeutic mRNA to extra-hepatic organs such as the lung, spleen, lymphoid organ, eye, and brain.
While LNPs provide a highly efficient platform for the in vivo delivery of RNA by overcoming various biological barriers, several challenges remain to be resolved for further development and regulatory approval. These include a lack of targeted delivery to extrahepatic organs and a gradual loss of therapeutic potency with repeated doses. Overall, LNPs have the potential to revolutionize the delivery of a wide range of therapeutics, including RNA-based therapies and gene editing tools, but further research and development are needed to fully realize this potential.
Reference:
Copyright © Creative Biogene. All rights reserved.